Adjuvant medroxyprogesterone acetate in high-risk endometrial cancer
- 1 September 1998
- journal article
- research article
- Published by Elsevier in International Journal of Gynecologic Cancer
- Vol. 8 (5) , 387-391
- https://doi.org/10.1046/j.1525-1438.1998.09865.x
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Adjuvant progestagen therapy for the treatment of endometrial cancer: review and meta-analyses of published randomised controlled trialsEuropean Journal of Obstetrics & Gynecology and Reproductive Biology, 1996
- Pelvic lymphadenectomy in high risk endometrial cancerInternational Journal of Gynecologic Cancer, 1996
- A randomized trial of adjuvant progestagen in early endometrial cancerCancer, 1989
- Increased uterine prostaglandin E receptors in menorrhagic womenBJOG: An International Journal of Obstetrics and Gynaecology, 1988
- Surgical staging of gynecologic malignanciesCancer, 1987
- Endometrial carcinoma: Steroid receptors and response to medroxyprogesterone acetateGynecologic Oncology, 1985
- Medroxyprogesterone acetate (depo-provera) vs. hydroxyprogesterone caproate (Delalutin) in women with metastatic endometrial adenocarcinomaCancer, 1980
- Adjuvant Progesterone Therapy for Stage I Endometrial CarcinomaInternational Journal of Gynecology & Obstetrics, 1978
- Adjuvant progestogen therapy in the primary definitive treatment of endometrial cancerGynecologic Oncology, 1974